SATSUMA PHARMACEUTICALS, INC. (STSA) News
Filter STSA News Items
STSA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STSA News Highlights
- STSA's 30 day story count now stands at 2.
- Over the past 27 days, the trend for STSA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, AAN and LEV are the most mentioned tickers in articles about STSA.
Latest STSA News From Around the Web
Below are the latest news stories about SATSUMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate STSA as an investment opportunity.
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineJanuary 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma lev |
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingSOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-p |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! |
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?Prometheus Biosciences (RXDX) stock is on the rise Monday after the company revealed a $10.8 billion acquisition deal with Merck (MRK). |
Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?Satsuma Pharmaceuticals (STSA) stock is taking off on Monday after revealing an acquisition deal with Shin Nippon Biomedical Laboratories. |
Why Is Marpai (MRAI) Stock Down 40% Today?Marpai (MRAI) stock is taking a beating on Monday after the company announced a proposed public offering for its shares. |
Why Is SAI.TECH Global (SAI) Stock Down 32% Today?SAI.TECH Global (SAI) stock is down on Monday despite a lack of news concerning the Bitcoin (BTC-USD) mining and clean energy company. |
SNBL to Acquire Satsuma PharmaceuticalsTransaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Satsuma’s Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL SOUTH SAN FRANCISCO, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- S |
We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted STS101 New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in March 2023 - - Company seeking to maximize value for stockholders via strategic transaction - - ~36% workforce reduction to be implemented effective March 31, 2023 - - $52.5 million in cash, cash equivalents and marketable |